Evolus (EOLS)
(Delayed Data from NSDQ)
$16.55 USD
+0.11 (0.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.55 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.55 USD
+0.11 (0.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.55 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
Zacks News
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus (EOLS) delivered earnings and revenue surprises of -75% and 2.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
by Zacks Equity Research
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus (EOLS) delivered earnings and revenue surprises of -85.71% and 0.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
by Tirthankar Chakraborty
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Green Thumb Industries Inc. (GTBIF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
3 Top Stocks to Invest in for Amazing Earnings Acceleration
by Tirthankar Chakraborty
Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.
4 Stocks to Buy for Attractive Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 63.2% upside potential for Evolus, Inc. (EOLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 25% and 9.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 133.9% upside potential for Evolus, Inc. (EOLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -30.77% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 3.09% and 0.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -100% and 9.74%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -33.33% and 2.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -18.52% and 8.22%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -58.33% and 0.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.
Does Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Evolus, Inc. (EOLS) points to a 28.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Computer Programs and Systems (CPSI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Computer Programs and Systems (CPSI) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 34% Upside in Evolus, Inc. (EOLS): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Evolus, Inc. (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Has Evolus (EOLS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Evolus, Inc. (EOLS) and Computer Programs and Systems (CPSI) have performed compared to their sector so far this year.